Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-188afbad7741da761c6e6e81c9577944"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-188afbad7741da761c6e6e81c9577944"/>
<resource>
<Composition>
<id value="composition-en-188afbad7741da761c6e6e81c9577944"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-188afbad7741da761c6e6e81c9577944"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-188afbad7741da761c6e6e81c9577944</b></p><a name="composition-en-188afbad7741da761c6e6e81c9577944"> </a><a name="hccomposition-en-188afbad7741da761c6e6e81c9577944"> </a><a name="composition-en-188afbad7741da761c6e6e81c9577944-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/16/1141/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - somakit</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/16/1141/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp188afbad7741da761c6e6e81c9577944"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - somakit"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What SomaKit TOC is and what it is used for</li><li>What you need to know before SomaKit TOC is used</li><li>How SomaKit TOC is used</li><li>Possible side effects</li><li>How SomaKit TOC is stored</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What somakit is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What somakit is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>This medicine is a radiopharmaceutical for diagnostic use only. It contains the active substance edotreotide. Before it can be used, the powder in the vial is mixed with a radioactive substance called gallium (68Ga) chloride to make gallium (68Ga) edotreotide (this procedure is called radiolabelling).</p><p>Gallium (68Ga) edotreotide contains a small amount of radioactivity. After injection into a vein, it can make parts of the body visible to doctors during a medical imaging procedure called positron emission tomography (PET). This medical procedure obtains images of your organs to help locate abnormal cells or tumours, giving valuable information about your disease.</p><p>The use of SomaKit TOC involves exposure to small amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit from the procedure with the radiopharmaceutical outweighs the risk due to radiation.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take somakit"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take somakit"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>SomaKit TOC must not be used</p><ul><li>if you are allergic to edotreotide or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions Talk to your nuclear medicine doctor before you are given SomaKit TOC:</p><ul><li>if you experienced any signs of allergic reaction (listed in section 4) after previous administration of SomaKit TOC;</li><li>if you have kidney or liver problems (renal or hepatic disease);</li><li>if you are under 18 years of age;</li><li>if you have signs of dehydration before and after the examination;</li><li>if you have other medical conditions, such as high level of cortisol in the body (Cushing syndrome), inflammation, thyroid disease, other type of tumour (of pituitary gland, lung, brain, breast, immune system, thyroid, adrenal gland or others) or disease of the spleen (including previous trauma or surgery involving the spleen). Such conditions may be visible and affect the interpretation of the images. Your doctor may therefore perform additional scans and tests to confirm the findings on gallium (68Ga) edotreotide imaging.</li><li>if you have been recently vaccinated. Enlarged lymph nodes due to vaccination may become visible during gallium (68Ga) edotreotide imaging;</li><li>if you have been taking other medicines, such as somatostatin analogues and glucocorticoids, which may interact with SomaKit TOC;</li><li>if you are pregnant or believe you may be pregnant;</li><li>if you are breast-feeding.</li></ul><p>Your nuclear medicine doctor will inform you if you need to take any other special precaution before or after using SomaKit TOC.</p><p>Before administration of SomaKit TOC You should drink plenty of water before the start of the examination in order to urinate as often as possible during the first hours after the procedure to ensure that SomaKit TOC is removed as quickly as possible from your body.</p><p>Children and adolescents This medicine is not recommended in patients under 18 years of age because its safety and efficacy have not been established in this patient population.</p><p>Other medicines and SomaKit TOC Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines, including somatostatin analogues or glucocorticoids (also called corticosteroids), since they may interfere with the interpretation of the images. If you are taking somatostatin analogues you might be asked to stop your treatment for a short period of time.</p><p>Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given this medicine.</p><p>You must inform the nuclear medicine doctor before the administration of SomaKit TOC if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding. When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.</p><p>There is no information about the safety and the efficacy of the use of this medicine during pregnancy. Only essential investigations should be carried out during pregnancy, when the likely benefit far exceeds any risk to the mother and foetus.</p><p>If you are breast-feeding the nuclear medicine doctor may either delay the medical procedure until you are no longer breast-feeding or ask you to stop breast-feeding and to discard your milk until there is no radioactivity in your body (12 hours after the administration of SomaKit TOC). Please ask your nuclear medicine doctor when you can resume breast-feeding.</p><p>Driving and using machines It is considered unlikely that SomaKit TOC will affect your ability to drive or to use machines.</p><p>SomaKit TOC contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium free .</p></div>
</text>
</section>
<section>
<title value="3. How to take somakit"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take somakit"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>There are strict laws on the use, handling and disposal of radiopharmaceutical products. SomaKit TOC will only be used in special controlled areas. This medicine will only be handled and given to you by people who are trained and qualified to use it safely. These persons will take special care for the safe use of this medicine and will keep you informed of their actions.</p><p>The nuclear medicine doctor supervising the procedure will decide on the quantity of SomaKit TOC to be used in your case. It will be the smallest quantity necessary to get the desired information. The quantity to be administered usually recommended for an adult ranges from 100 MBq to 200 MBq (megabecquerel, the unit used to express radioactivity).</p><p>Administration of SomaKit TOC and conduct of the procedure After radiolabelling, SomaKit TOC is administered by intravenous injection. A single injection is sufficient to conduct the test that your doctor needs. After injection, you will be offered something to drink and asked to urinate immediately preceding the test.</p><p>Duration of the procedure Your nuclear medicine doctor will inform you about the usual duration of the procedure.</p><p>After administration of SomaKit TOC, you should:</p><ul><li>avoid any close contact with young children and pregnant women for 12 hours after the injection</li><li>urinate frequently in order to eliminate the medicine from your body.</li></ul><p>The nuclear medicine doctor will inform you if you need to take any special precautions after receiving this medicine. Contact your nuclear medicine doctor if you have any questions.</p><p>If you have been given more SomaKit TOC than you should An overdose is unlikely because you will only receive a single dose under controlled conditions by the nuclear medicine doctor supervising the procedure. However, in the case of an overdose, you will receive the appropriate treatment. Drinking and emptying your bladder frequently will help remove the radioactive substance from your body more quickly.</p><p>Should you have any further questions on the use of SomaKit TOC, please ask the nuclear medicine doctor who supervises the procedure.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Although no side effects have been reported, a potential risk of allergic reactions (hypersensitivity) exists with SomaKit TOC. Symptoms may include: warm flush, redness of the skin, swelling, itching, nausea and difficulty breathing. In the event of an allergic reaction you will receive the appropriate treatment from your medical staff.</p><p>Not known (frequency cannot be estimated from the available data):</p><ul><li>Stinging near the injection site</li></ul><p>The spleen is an organ located in the abdomen (belly). Some people are born with an extra spleen (an accessory spleen). Extra spleen tissue may also be found in the abdomen following surgery or trauma to the spleen (this is known as splenosis). Gallium (68Ga) edotreotide may make an accessory spleen or splenosis visible during medical imaging. There have been reports where this has been mistaken for a tumour. Your doctor may therefore perform additional scans and tests to confirm the findings on gallium (68Ga) edotreotide imaging (see section 2).</p><p>This radiopharmaceutical will deliver low amounts of ionising radiation associated with the least risk of cancer and hereditary abnormalities.</p><p>Reporting of side effects If you get any side effects talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store somakit"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store somakit"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.</p><p>The following information is intended for the specialist only.</p><p>Keep this medicine out of the sight and reach of children.</p><p>SomaKit TOC must not be used after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2 C to 8 C). Store in the original package in order to protect from light.</p><p>After radiolabelling, SomaKit TOC should be used within 4 hours. Do not store above 25 C after radiolabelling.</p><p>SomaKit TOC must not be used if there are visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Wait for the level of radioactivity to decay adequately before throwing away radioactive products. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What SomaKit TOC contains</p><ul><li>The active substance is edotreotide. Each vial of powder for solution for injection contains 40 micrograms of edotreotide.</li><li>The other ingredients are: 1,10-phenanthroline, gentisic acid, mannitol, formic acid, sodium hydroxide, water for injections. After radiolabelling, the solution obtained also contains hydrochloric acid.</li></ul><p>What SomaKit TOC looks like and contents of the pack SomaKit TOC is a kit for radiopharmaceutical preparation containing:</p><ul><li>A glass vial with black flip-off cap containing a white powder.</li><li>A cyclic olefin polymer vial with yellow flip-off cap containing a clear and colourless solution.</li></ul><p>The radioactive substance is not part of the kit and should be added during the preparation steps before injection.</p><p>Marketing authorisation holder Advanced Accelerator Applications 8-10 Rue Henri Sainte-Claire Deville 92500 Rueil-Malmaison France</p><p>Manufacturer Advanced Accelerator Applications (Italy) S.r.l. Via Crescentino snc, 13040 Saluggia (VC), Italy</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Novartis Pharma N.V. T l/Tel: +32 2 246 16 Lietuva SAM Nordic vedija Tel: +46 8 720 58<br/>Novartis Bulgaria EOOD : +359 2 489 98 Luxembourg/Luxemburg Novartis Pharma N.V. T l/Tel: +32 2 246 16 esk republika M.G.P. spol. s r.o. Tel: +420 602 303 Magyarorsz g Novartis Hung ria Kft. Tel.: +36 1 457 65 Danmark SAM Nordic Sverige Tel: +46 8 720 58 Malta Novartis Pharma Services Inc. Tel: +356 2122 2Deutschland Novartis Radiopharmaceuticals GmbH Tel: +49 911 273 0</p><p>Nederland Novartis Pharma B.V. Tel: +31 88 04 52 Eesti SAM Nordic Rootsi Tel: +46 8 720 58 Norge SAM Nordic Sverige Tlf: +46 8 720 58</p><p>: +30 22920 63 sterreich Novartis Pharma GmbH Tel: +43 1 86 6Espa a Advanced Accelerator Applications Ib rica, S.L.U. Tel: +34 97 6600 Polska Advanced Accelerator Applications Polska Sp. z o.o. Tel.: +48 22 275 56 France Advanced Accelerator Applications T l: +33 1 55 47 63 Portugal Novartis Farma - Produtos Farmac uticos, S.A. Tel: +351 21 000 8Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 Rom nia Novartis Pharma Services Romania SRL Tel: +40 21 31299 Ireland Novartis Ireland Limited Tel: +353 1 260 12 Slovenija Advanced Accelerator Applications Francija Tel: +33 1 55 47 63 sland SAM Nordic Sv j<br/>S mi: +46 8 720 58 Slovensk republika MGP, spol. s r.o. Tel: +421 254 654 Italia Advanced Accelerator Applications (Italy) S.r.l Tel: +39 0125 561Suomi/Finland SAM Nordic Ruotsi/Sverige Puh/Tel: +46 8 720 58</p><p>: +30 22920 63Sverige SAM Nordic Tel: +46 8 720 58 Latvija SAM Nordic Zviedrija Tel: +46 8 720 58 United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276 698This leaflet was last revised in</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp188afbad7741da761c6e6e81c9577944"/>
<resource>
<MedicinalProductDefinition>
<id value="mp188afbad7741da761c6e6e81c9577944"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp188afbad7741da761c6e6e81c9577944"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp188afbad7741da761c6e6e81c9577944</b></p><a name="mp188afbad7741da761c6e6e81c9577944"> </a><a name="hcmp188afbad7741da761c6e6e81c9577944"> </a><a name="mp188afbad7741da761c6e6e81c9577944-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/16/1141/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: SomaKit TOC 40 micrograms kit for radiopharmaceutical preparation</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/16/1141/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="SomaKit TOC 40 micrograms kit for radiopharmaceutical preparation"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
